{"id":64621,"date":"2026-05-07T14:00:40","date_gmt":"2026-05-07T06:00:40","guid":{"rendered":"https:\/\/flcube.com\/?p=64621"},"modified":"2026-05-07T14:00:41","modified_gmt":"2026-05-07T06:00:41","slug":"sino-biopharmaceutical-initiates-phase-iii-trial-for-lm-108-ccr8-targeted-antibody-in-gastric-cancer-following-breakthrough-therapy-designations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64621","title":{"rendered":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced the <strong>first patient enrollment<\/strong> in a <strong>Phase III regulatory study<\/strong> for <strong>LM-108<\/strong>, a <strong>CCR8-targeted monoclonal antibody (mAb)<\/strong> co-developed by its subsidiary <strong>LaNova Medicines<\/strong> following their strategic deal in <strong>November 2024<\/strong>. The trial will evaluate LM-108 in combination with a <strong>PD-1 inhibitor<\/strong> for <strong>second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-milestone\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Developer<\/strong><\/td><td>Sino Biopharmaceutical Ltd. (HKG: 1177) \/ LaNova Medicines (subsidiary)<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III regulatory trial initiated<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LM-108 (CCR8-targeted monoclonal antibody)<\/td><\/tr><tr><td><strong>Combination Partner<\/strong><\/td><td>PD-1 inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Second-line CCR8-positive locally advanced or metastatic G\/GEJ adenocarcinoma<\/td><\/tr><tr><td><strong>Milestone Date<\/strong><\/td><td>First patient enrolled \u2013 7 May 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-recognition-amp-prior-designations\">Regulatory Recognition &amp; Prior Designations<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-breakthrough-therapy-designations-btds\">Breakthrough Therapy Designations (BTDs)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MSI-H\/dMMR Advanced Solid Tumors<\/strong>: LM-108 + toripalimab for patients who progressed following prior immune checkpoint inhibitor therapy<\/li>\n\n\n\n<li><strong>CCR8-Positive Advanced G\/GEJ Adenocarcinoma<\/strong>: LM-108 + toripalimab for patients who failed first-line standard therapy<\/li>\n<\/ul>\n\n\n\n<p>These <strong>dual Breakthrough Therapy Designations<\/strong> from Chinese regulatory authorities highlight the significant unmet medical need and promising early clinical data supporting LM-108&#8217;s development across multiple tumor types.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-strategy-amp-innovation\">Clinical Strategy &amp; Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>CCR8 (C-C chemokine receptor type 8)<\/strong> \u2013 expressed on immunosuppressive regulatory T cells (Tregs) in tumor microenvironment<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Depletes tumor-infiltrating Tregs while sparing peripheral Tregs, potentially enhancing anti-tumor immunity without systemic autoimmunity<\/td><\/tr><tr><td><strong>Combination Rationale<\/strong><\/td><td>Synergistic effect with PD-1 inhibitors by simultaneously targeting complementary immune evasion pathways<\/td><\/tr><tr><td><strong>Patient Selection<\/strong><\/td><td><strong>CCR8-positive tumors<\/strong> \u2013 biomarker-driven approach to identify patients most likely to benefit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The Phase III trial represents a <strong>precision medicine strategy<\/strong> targeting a molecularly defined patient population with high unmet need in gastric cancer, one of China&#8217;s most prevalent malignancies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-implications\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gastric Cancer Burden<\/strong>: China accounts for approximately <strong>40% of global gastric cancer cases<\/strong>, creating substantial demand for effective second-line therapies.<\/li>\n\n\n\n<li><strong>Immunotherapy Evolution<\/strong>: The combination of <strong>novel immune targets<\/strong> (CCR8) with <strong>established checkpoint inhibitors<\/strong> (PD-1) represents the next frontier in immuno-oncology beyond monotherapy approaches.<\/li>\n\n\n\n<li><strong>Subsidiary Integration<\/strong>: The successful advancement of LM-108 validates Sino Biopharmaceutical&#8217;s <strong>November 2024 acquisition<\/strong> of LaNova Medicines and demonstrates effective pipeline integration.<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: As one of the first CCR8-targeted antibodies to reach Phase III globally, LM-108 could establish <strong>first-mover advantage<\/strong> in this emerging therapeutic class.<\/li>\n<\/ul>\n\n\n\n<p>The initiation of this pivotal trial positions Sino Biopharmaceutical to potentially deliver a <strong>transformative treatment option<\/strong> for gastric cancer patients with limited therapeutic alternatives in the second-line setting.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory designations, and market opportunities for LM-108. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700024_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026050700024_c.\"><\/object><a id=\"wp-block-file--media-00647f6b-f9a7-4117-a89f-12c91ac1c99d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700024_c.pdf\">2026050700024_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700024_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-00647f6b-f9a7-4117-a89f-12c91ac1c99d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[908,313],"class_list":["post-64621","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64621\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64621\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T06:00:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T06:00:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations\",\"datePublished\":\"2026-05-07T06:00:40+00:00\",\"dateModified\":\"2026-05-07T06:00:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64621#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64621\",\"name\":\"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-07T06:00:40+00:00\",\"dateModified\":\"2026-05-07T06:00:41+00:00\",\"description\":\"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\\\/gastroesophageal junction (G\\\/GEJ) adenocarcinoma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64621\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64621#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64621","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations","og_description":"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma.","og_url":"https:\/\/flcube.com\/?p=64621","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-07T06:00:40+00:00","article_modified_time":"2026-05-07T06:00:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64621#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64621"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations","datePublished":"2026-05-07T06:00:40+00:00","dateModified":"2026-05-07T06:00:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64621"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64621#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64621","url":"https:\/\/flcube.com\/?p=64621","name":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-07T06:00:40+00:00","dateModified":"2026-05-07T06:00:41+00:00","description":"Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64621#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64621"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64621#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Initiates Phase III Trial for LM-108 \u2013 CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64621"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64621\/revisions"}],"predecessor-version":[{"id":64623,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64621\/revisions\/64623"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}